CHRN EKSO BIONICS HOLDINGS, INC.

CIK 0001549084 50 ready 8-Ks latest July 1, 2026, 4:43 PM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 1 baseline Risk accumulating: auditor change (2), repeated leadership change (13), risk events (2)

Ready 8-Ks 50

Latest filing July 1, 2026, 4:43 PM ET

Top materiality 0.95

Event mix other_material ×17 · earnings ×15 · m_and_a ×6

Sentiment 11 pos · 11 neg · 28 neu

Latest earnings reported 2025-Q2

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for CHRN

Highest-materiality recent filing

Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.

May 5, 2026, 7:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 4.01 item 5.01 item 5.02 item 5.03 item 9.01 ◈ executive_change ×11◈ Governance Changes ×3◈ Auditor Changes ×2◈ Equity Issuances ×2◈ M&A Transactions

Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.
Company issued 138,216,820 new shares to Contributor for 100% of Cloud; post-merger shares outstanding 143,093,381.

Read filing →

July 1, 2026, 4:43 PM ET other material materiality 0.70 neutral item 1.01 item 3.01 item 8.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01 ◈ executive_change

ChronoScale Corporation reorganizes into holding company structure, becomes ChronoScale Holdings Corporation

On July 1, 2026, ChronoScale completed a holding company reorganization, merging with a subsidiary of newly formed ChronoScale Holdings.
June 30, 2026, 5:14 PM ET other material materiality 0.75 neutral item 9.01 item 8.01

ChronoScale files Cloud financials: FY2025 revenue $84.4M, net loss $72.7M

Cloud FY2025 revenue $84.4M (up from $29.0M in FY2024); net loss $72.7M vs $75.3M prior year.
June 26, 2026, 4:50 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 9.01

ChronoScale enters $100M unsecured demand note from Applied Digital Corporation

Applied Digital Corporation makes $100M unsecured demand grid promissory note available to ChronoScale.
June 4, 2026, 4:15 PM ET other material materiality 0.65 negative item 2.05

Chronoscale plans to divest Ekso Bionics, focus on cloud business

Board committed on May 29, 2026 to divest wholly owned subsidiary Ekso Bionics, Inc.
May 20, 2026, 5:14 PM ET other material materiality 0.70 neutral item 5.02 item 9.01

ChronoScale Amends Phantom PSU Awards for Three Executives After Change in Control

Scott Davis's Phantom PSU amended to settle as 109,357 shares of common stock plus $1,000,000 cash.
May 5, 2026, 7:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 4.01 item 5.01 item 5.02 item 5.03 item 9.01 ◈ executive_change ×11◈ Governance Changes ×3◈ Auditor Changes ×2◈ Equity Issuances ×2◈ M&A Transactions

Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.

Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.
May 4, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 9.01 ◈ Equity Issuances◈ Material Agreements

Ekso Bionics to close business combination with Applied Digital, PIPE $15.75M, ticker becomes CHRN

Business combination with Applied Digital subsidiary closes May 5, 2026; company renames to ChronoScale Corporation.
February 17, 2026, 6:59 PM ET M&A materiality 0.95 negative item 1.01 item 2.02 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 9.01 ◈ Governance Changes ×3◈ Equity Issuances◈ Material Agreements

Ekso to merge with Applied Digital Cloud in reverse merger; APLD to own ~97%, rename to ChronoScale

Exchange: Ekso issues 138.2M shares to APLD for 100% of Cloud; APLD expects ~97% ownership of combined company.
January 22, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 5.03 item 9.01 ◈ Equity Issuances ×2◈ Governance Changes◈ Material Agreements

Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants

Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.
December 29, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Ekso Bionics and Applied Digital propose business combination; EKSO holders get ~3% of ChronoScale

Applied Digital to spin out cloud business, combine with EKSO to form ChronoScale Corporation.
October 30, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 item 8.01 item 9.01

Ekso Bionics raises $3.2M net in registered direct offering of 769,490 shares at $4.81

Sold 769,490 shares at $4.81 per share to institutional investors; net proceeds ~$3.2M.
October 28, 2025, 7:59 PM ET other material materiality 0.75 negative item 2.02 item 9.01

Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry

Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.
September 17, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 1.02 item 2.03 item 9.01 ◈ Debt Financings

Ekso Bionics enters $2M secured loan with B. Riley at 10% interest

Agreement with B. Riley Commercial Capital for up to $2.0M secured term loan, maturing Sept 14, 2026 or upon qualified equity raise of $2.4M.
July 28, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M

Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
May 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Ekso Bionics updates reverse stock split effective date to June 2, 2025

Reverse stock split at 1-for-15 effective June 2, 2025; originally planned May 27.
May 20, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.07 item 8.01 item 9.01

Ekso Bionics approves 1-for-15 reverse stock split effective May 27, 2025 to regain Nasdaq compliance

Reverse split ratio set at 1-for-15; effective 12:01 a.m. PT on May 27, 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution

Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.
March 17, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 3.03 item 9.01

Ekso Bionics raises $4.15M via warrant exercise; issues new 10.5M-share warrant at $0.4239

Existing holder exercises 9.8M warrants for $4.15M at $0.4239/share; company receives cash proceeds.
March 3, 2025, 6:59 PM ET earnings materiality 0.72 positive item 2.02 item 9.01

Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024

Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.
January 13, 2025, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 8.01 item 9.01

Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary

Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
December 13, 2024, 6:59 PM ET regulatory materiality 0.80 negative item 3.01

Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply

Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.
September 3, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

Ekso Bionics raises ~$5.1M net in underwritten public offering of units with warrants

Issued 3.1M units at $1.00/unit (share + Series A/B warrants) and 2.9M pre-funded units at $0.9990/unit.
July 29, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share

Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
April 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal

Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.
March 4, 2024, 6:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

Ekso Bionics reports record 2023 revenue of $18.3M, up 42% YoY

Full-year 2023 revenue $18.3M (FY22: $12.9M); sold 151 EksoHealth units.
January 16, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Ekso Bionics raises ~$4.0M in registered direct offering of 2.97M shares at $1.55/share

Sold 2,967,742 common shares at $1.55 each; net proceeds ~$4.0M after fees and expenses.
January 5, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M

Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).
November 14, 2023, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

Ekso Bionics regains Nasdaq minimum bid price compliance

Received Nasdaq written notice on Nov 14, 2023, confirming compliance with $1.00 minimum bid price rule.
October 26, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

Ekso Bionics Q3 revenue up 38% to $4.6M; net loss narrows to $0.24/share

Revenue of $4.6M, up 38% YoY; gross margin improved to 53% from 51%.
July 27, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share

Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.
April 27, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M

Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.
March 28, 2023, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Ekso Bionics reports FY 2022 revenue up 15% to $12.9M, net loss widens to $15.1M

Full-year revenue $12.9M (up 15% YoY); Q4 revenue $3.6M vs $4.1M year ago.
February 16, 2023, 6:59 PM ET M&A materiality 0.70 negative item 9.01

Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022

Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.
December 5, 2022, 6:59 PM ET M&A materiality 0.75 positive item 2.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×3◈ M&A Transactions

Ekso Bionics acquires Parker HMC business for $10M, appoints Scott Davis as CEO

Acquired Parker Hannifin's Human Motion and Control business for $10M ($5M cash + $5M zero-coupon note payable quarterly over 4 years).
November 3, 2022, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Ekso Bionics Q3 revenue up 9.2% to $3.3M; net loss widens to $4.3M; record 33 EksoNR bookings

Revenue $3.3M (+9.2% YoY); nine-month revenue $9.4M (+30.6% YoY).
July 28, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M

Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.